BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22949868)

  • 1. MUC16/CA125 in the context of modular proteins with an annotated role in adhesion-related processes: in silico analysis.
    Jankovic M; Mitic N
    Int J Mol Sci; 2012; 13(8):10387-10400. PubMed ID: 22949868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
    White B; Patterson M; Karnwal S; Brooks CL
    Proteins; 2022 May; 90(5):1210-1218. PubMed ID: 35037700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
    Morgado M; Sutton MN; Simmons M; Warren CR; Lu Z; Constantinou PE; Liu J; Francis LL; Conlan RS; Bast RC; Carson DD
    Oncotarget; 2016 Mar; 7(12):14871-84. PubMed ID: 26918940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I; Garde-Granger P; Bessette P; Piché A
    BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16.
    Bouanene H; Miled A
    Dis Markers; 2010; 28(6):385-94. PubMed ID: 20683153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
    Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
    J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
    Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
    Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
    Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
    Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MUC16: The Novel Target for Tumor Therapy].
    Gao R; Lou N; Han X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
    Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
    Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
    Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
    Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.
    Zhang M; Cheng S; Jin Y; Zhao Y; Wang Y
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188503. PubMed ID: 33421585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the molecular nature of ovarian cancer biomarker CA125.
    Weiland F; Martin K; Oehler MK; Hoffmann P
    Int J Mol Sci; 2012; 13(8):10568-10582. PubMed ID: 22949880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
    Yin BW; Dnistrian A; Lloyd KO
    Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
    Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
    PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.